Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH MEDIA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

First-in-Class Masked Antibody Therapeutic Effective in Fighting Pancreatic Tumor Models

By BiotechDaily International staff writers
Posted on 13 Nov 2013
In research conducted with multiple preclinical models, the data indicate that a new masked antibody therapeutic has been shown to be effective in fighting pancreatic cancer models as both a single agent and in combination with gemcitabine, a currently available antimetabolite drug approved by the US Food and Drug Administration (FDA) to treat pancreatic and other cancers.

Furthermore, the data show that the agent is locally activated in the tumor microenvironment and it spares systemic side effects, such as skin toxicity associated with systemically blocking Notch pathway signaling.

CytomX Therapeutics (South San Francisco, CA, USA), a Probody therapeutics company, recently presented data demonstrating preclinical proof-of-concept of the company’s Jagged Probody blocking Jagged-dependent Notch signaling for the treatment of cancer. These data were presented for the first time at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics being held October 19-23, 2013, in Boston (MA, USA).

“The Notch pathway is centrally implicated in tumor biology and is involved in the progression of a number of cancers, including pancreatic cancer, triple negative breast cancer, and multiple myeloma,” stated Henry Lowman, PhD, chief scientific officer of CytomX and senior author of the poster. “Our anti-Jagged Probody represents a novel approach to targeting the Notch signaling pathway, and our data establish preclinical proof-of-concept that selective activation of CTX-033 in the tumor microenvironment results in robust efficacy with an acceptable therapeutic index.”

Probodies are masked antibodies that remain inert in healthy tissue but are activated or “unmasked” in the disease microenvironment. CytomX is developing a novel, first-in-class Probody program that blocks Notch signaling by both the Jagged-1 and Jagged-2 ligands locally in the tumor microenvironment.

“Following our recent publication on the Probody platform in Science Translational Medicine, these data provide further validation of our unique and highly differentiated Probody approach,” said Sean McCarthy, D.Phil., chief executive officer of CytomX. “Our Jagged Probody program showcases the value of the Probody platform in targeting a pathway that has been challenging with traditional antibodies because of healthy tissue toxicities, and we look forward to advancing this novel concept towards clinical testing.”

CytomX’s Probody platform represents a disruptive approach to discovering and developing the next-generation of antibody therapeutics and is enabling the development of a diversified pipeline in major unmet medical needs including cancer and inflammation. Probodies are masked antibodies that remain inert in healthy tissue but are activated specifically in the disease microenvironment. This breakthrough selectivity allows CytomX to drug previously undruggable antibody targets, unlock new therapeutic targets for antibody-drug conjugates (ADCs), and focus activity in the tumor microenvironment, thereby redefining the landscape for therapeutic antibodies.

Related Links:

CytomX Therapeutics



Channels

Genomics/Proteomics

view channel
Image: The osteochondroretricular stem cell is a newly identified type of bone stem cell that appears to be vital to skeletal development and may provide the basis for novel treatments for osteoarthritis, osteoporosis, and bone fractures. In this illustration of the head of a femur, osteochondroretricular stem cells are visualized in red (Photo courtesy of Dr. Timothy Wang, Columbia University).

Gremlin 1 Expression Distinguishes Stem Cells Able to Regenerate Bones and Cartilage in Adult Mice

A newly identified type of stem cell in the bone marrow of adult mice was found to be capable of regenerating both bone and cartilage. Investigators at Columbia University (New York, NY, USA) reported... Read more

Drug Discovery

view channel

Curcumin Used to Treat Alzheimer’s Disease

Curcumin, a natural substance found in the spice turmeric, has been used by many Asian cultures for centuries. Now, new research suggests that a close chemical analog of curcumin has properties that may make it useful as a treatment for Alzheimer’s disease. “Curcumin has demonstrated ability to enter the brain, bind... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Lab Technologies

view channel
Image: MIT researchers have designed a microfluidic device that allows them to precisely trap pairs of cells (one red, one green) and observe how they interact over time (Photo courtesy of Burak Dura, MIT).

New Device Designed to See Communication between Immune Cells

The immune system is a complicated network of many different cells working together to defend against invaders. Effectively combating an infection depends on the interactions between these cells.... Read more

Business

view channel

Program Designed to Provide High-Performance Computing Cluster Systems for Bioinformatics Research

Dedicated Computing (Waukesha, WI, USA), a global technology company, reported that it will be participating in the Intel Cluster Ready program to deliver integrated high-performance computing cluster solutions to the life sciences market. Powered by Intel Xeon processors, Dedicated Computing is providing a range of... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.